epigallocatechin gallate has been researched along with daunorubicin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Bulic, B; Mandelkow, E; Pickhardt, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Campbell, KJ; O'Shea, JM; Perkins, ND | 1 |
| Chan, TH; Davenport, A; Dou, QP; Frezza, M; Ge, Y; Huo, C; Shen, M | 1 |
| Dang, Y; Ding, L; Hu, H; Hu, X; Huang, Q; Huang, W; Ji, X; Jiang, S; Li, J; Liu, JO; Liu, S; Shen, S; Yang, X; Yu, L | 1 |
| Chen, YY; Fu, LX; Gan, RZ; Li, L; Liang, G; Lv, MX; Zhang, XX; Zhou, H; Zhou, JL; Zhu, HQ | 1 |
| Erdődi, F; Kiss, A; Tóth, E | 1 |
| Bae, KH; Chen, Q; Kurisawa, M; Lai, F; Oruc, B; Osato, M | 1 |
1 review(s) available for epigallocatechin gallate and daunorubicin
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; Protein Binding; Protein Conformation; Structure-Activity Relationship; tau Proteins | 2013 |
8 other study(ies) available for epigallocatechin gallate and daunorubicin
| Article | Year |
|---|---|
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport, Active; Biomarkers; Cells, Cultured; Drug Interactions; Fluorescent Dyes; Humans | 2003 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Catechin; Cell Line, Tumor; Daunorubicin; DNA Damage; Doxorubicin; Enzyme Inhibitors; Free Radicals; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Intercalating Agents; Mitoxantrone; NF-kappa B; Osteosarcoma; Oxidation-Reduction; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase II Inhibitors; Transcription, Genetic | 2006 |
Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Cytarabine; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Leukemia; Molecular Structure; Pentacyclic Triterpenes; Plant Extracts; Prodrugs; Triterpenes | 2010 |
Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Topics: Alcohol Oxidoreductases; Animals; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Carcinoma, Hepatocellular; Catechin; Daunorubicin; Humans; Liver Neoplasms; Mice; Tumor Cells, Cultured | 2010 |
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Topics: Alcohol Oxidoreductases; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Hepatocellular; Cardiotoxicity; Catechin; Cell Proliferation; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Heart Rate; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Activation of Myosin Phosphatase by Epigallocatechin-Gallate Sensitizes THP-1 Leukemic Cells to Daunorubicin.
Topics: Antineoplastic Agents; Catechin; Cell Proliferation; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Myosin-Light-Chain Phosphatase; Structure-Activity Relationship; THP-1 Cells; Tumor Cells, Cultured | 2021 |
Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia.
Topics: Apoptosis; Catechin; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Tea | 2022 |